Ethics & Regulatory

Amendment - IRAS Submission (July 2020)

 

Amendment - New Clinical Trial Authorisation (July 2020)

 

Amendment  - Enzalutamide IB (RSI) (July 2020)

 

Amendment - Degarelix SPC (RSI) (April 2020)

 

Amendment - IMP labels (February 2020)

 

Amendment - Change of Sponsor, PIS update following Arm K pause, and RSI 2019-2020

REC and HRA (Change of Sponsor, PIS update, RSI update):

MHRA (Change of Sponsor):

MHRA (RSI update):

 

Amendment - Hormone Patch Application Information Sheet v1.0

 

Amendment - Consent Form v19.0 and PIS General v19.0, PIS Arm A v13.0, PIS Arm L v4.0

 

Protocol Version 19.0

 

Amendment - Enzalutamide IB Version 9.0

 

Protocol Version 17.0 

 

Amendment - Abiraterone Lay Summary 

 

Protocol Version 16.0 

 

Amendment - End of Arm H

 

Protocol Version 15.0 

 

Amendment - End of Arm J

 

Protocol Version 14.0 

 

Amendment - Patient Letter

 

Amendment - Original Comparison Summary & Additional Research PIS

 

Protocol Version 13.0

 

Amendment - End of Arm G

 

Protocol Version 12.0

 

Amendment - PIS General

 

Protocol Version 11.0

 

Protocol Version 10.0

 

Protocol Version 9.0

 

Protocol Version 8.0

 

Protocol Version 7.0

 

 

Protocol Version 6.0

 

Protocol Version 5.0

 

Protocol Version 4.0

 

Protocol Version 3.0

 

Protocol Version 2.0

 

Initial

 

STAMPEDE

Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.